• 6분 읽기
• 2025년 8월 1일 게시
안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
For as long as I can remember, the 'patent cliff' has been the great bogeyman of the pharmaceutical world. It’s the moment a company’s blockbuster drug, its golden goose, loses legal protection and gets swamped by a sea of cheap generic copies. The story was always the same. Revenues would fall off a cliff, executives would panic, and investors would run for the hills. It was seen as an inevitable, terrifying part of the industry’s life cycle.
And then along came AbbVie, a company that was supposed to be the poster child for this very disaster. Its drug, Humira, was the best selling medicine on the planet. When its patent expired, the script was written. Yet, AbbVie decided not to read it. Instead of collapsing, the company actually raised its profit outlook. It seems the bogeyman might not be so scary after all, provided you have a plan.
So, what happened? Did AbbVie discover some sort of corporate magic? Not quite. The answer is far more interesting, and frankly, more reassuring for a pragmatic investor. For years, whilst Humira was printing money, AbbVie was quietly pouring billions into its research pipeline, developing the next generation of treatments.
When Humira’s day of reckoning finally arrived, two new drugs, Skyrizi and Rinvoq, were already waiting in the wings. Their sales surged, more than making up for the decline in the older drug. This wasn't a story of survival, it was a masterclass in succession planning. AbbVie didn't just dodge the bullet, it reloaded with something better. To me, this signals a fundamental shift. The patent cliff is no longer an endpoint, but a transition point for the smartest companies in the sector.
This episode provides a clear blueprint for what a modern, resilient pharmaceutical giant should look like. The strategy is simple in theory, but fiendishly difficult in practice. It involves having the discipline and foresight to invest heavily in research and development, even when your current cash cow is performing beautifully. It’s about playing the long game, not just milking the present.
Of course, not every company has the scientific muscle or the deep pockets to pull this off. Some will inevitably stumble. But for investors, this creates a fascinating dynamic. It’s no longer about just backing a company with one blockbuster drug. It’s about identifying the firms with a proven ability to innovate and build a pipeline that can weather these storms. Think of Pfizer, with its sprawling pipeline covering everything from cancer to rare diseases, or Vertex, which has built a formidable fortress by specialising in specific, complex conditions. They understand that the future isn't about protecting one castle, it's about building an empire.
The market seems to be catching on. Regulators and healthcare systems are increasingly rewarding genuine innovation over cheap imitation. A truly groundbreaking treatment that offers better patient outcomes can still command a premium price, creating a powerful incentive for companies to focus on real scientific progress. The game is changing from a defensive crouch to an offensive sprint towards the next discovery.
This changes how we should view the sector. The challenge is to find those companies with the right combination of a strong pipeline, proven development skills, and a strategic approach to their product lifecycle. It’s this very thinking that has led analysts to group together promising companies in this space, creating investment themes like Beyond The Patent Cliff: Pharma's New Growth Engines which focuses on firms with the potential to replicate this success.
However, let’s not get carried away. Investing in pharmaceuticals will always carry significant risks. Drug development is a high stakes game of chance. Clinical trials can, and often do, fail at the final hurdle. Regulatory approval is never a given, and a company’s multi billion dollar bet can evaporate overnight. This is not a sector for the faint of heart, and thorough research is non negotiable.
전체 바스켓 보기:Beyond The Patent Cliff: Pharma's New Growth Engines
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기